Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
Psyence BioMed to advance development of ibogaine after Trump announcement
Psyence BioMed said it intends to support development of ibogaine after President Trump signaled progress on regulatory steps and research funding. CEO Jody Aufrichtig and CFO Warwick Corden‑Lloyd are meeting with stakeholders in Texas to discuss clinical, regulatory and policy opportunities. The company, via PsyLabs, has access to GMP‑compliant manufacturing and stocks of ibogaine hydrochloride, but stressed that ibogaine remains controlled in the US and no clinical trials for the planned products have yet been conducted. » More on de.investing.com
Psyence Biomedical reports quarterly loss of $0.51 per share
Psyence Biomedical released the numbers for the quarter ended 30 September 2025 at the investor conference on 20 November 2025 and reported an EPS of -$0.51. By comparison, the company had earned $4.14 per share in the same period a year earlier. » More on finanzen.net
Financials
| (EUR) | Sep 2025 | |
|---|---|---|
| Revenue | 0.00 | - |
| Gross profit | −1.13k | - |
| Net profit | −641.87k | - |
| EBITDA | −638.39k | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 70.98k€ |
Number of shares | 19.02k |
52-week high/low | 185,67€ - 1,65€ |
| Dividends | No |
Beta | 1,67 |
P/E ratio | 0,00 |
PEG ratio | 0,00 |
P/B ratio | 0,00 |
P/S ratio | 0,00 |
Company profile
| Name | PSYENCE BIOMEDICAL LTD. |
| CEO | Jody Aufrichtig |
| Employees | 12 |
Discover assets
Shareholders of PSYENCE BIOMEDICAL LTD. also invest in the following assets
